PMV Pharmaceuticals releases rezatapopt Phase 2 interim results on Sept 10, 2025

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. (PMVP) filed an 8-K reporting a material event: the company issued a press release and hosted an investor webinar on September 10, 2025 to present interim monotherapy data for rezatapopt from the PYNNACLE Phase 2 trial in multiple solid tumors with a TP53 Y220C mutation. The press release is attached as Exhibit 99.2 and is incorporated by reference into the filing.

The filing notes the public dissemination of clinical interim results and the webinar but does not include the data tables or numerical results within the 8-K text itself. No financial results, enrollment counts, regulatory actions, or next-step timelines are disclosed in the provided excerpt.

Positive

• Public disclosure of interim Phase 2 PYNNACLE monotherapy data for rezatapopt
• Company hosted an investor webinar on September 10, 2025 to review the interim data
• Press release is formally attached as Exhibit 99.2 and incorporated by reference

Negative

• The 8-K excerpt does not include numerical results (efficacy, safety, enrollment) for the interim data
• No regulatory milestones, timelines, or financial impact are disclosed in the provided content
• The filing provides notice of disclosure only; investors must locate Exhibit 99.2 for material metrics

Insights

Clinical Development Analyst

Interim Phase 2 results were publicly shared; specifics are not included in the filing.

PMV disclosed that interim monotherapy data for rezatapopt in the PYNNACLE Phase 2 trial were released via press release and a webinar on September 10, 2025. The filing confirms public communication of clinical data but does not contain the actual efficacy or safety figures.

What it means: investors must consult the attached Exhibit 99.2 press release or webinar materials for measurable endpoints such as response rates, duration, or safety signals; the 8-K itself is a notice of the disclosure rather than a source of data.

Investor Relations Analyst

Material event likely to affect investor attention; materiality depends on disclosed results in Exhibit 99.2.

The 8-K documents a material communication event—release of interim clinical data and an investor webinar—both of which can move market perception for a clinical-stage biotech like PMV. The filing cites the press release as Exhibit 99.2 and confirms the date of public disclosure as September 10, 2025.

Why it matters: because the filing itself omits numerical outcomes, market reaction will depend entirely on the content of the attached press release and webinar comments; investors should review those exhibits for concrete metrics and any described next steps.

false 0001699382 0001699382 2025-09-10 2025-09-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2025

PMV Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39539		46-3218129
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

400 Alexander Park Drive, Suite 301 Princeton, NJ		08540
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (609) 642-6670

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		PMVP		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

The webinar presentation used in connection with the webinar described in Item 8.01 below is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

The webinar presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

Item 8.01 Other Events.

On September 10, 2025, PMV Pharmaceuticals, Inc. (the “Company”) issued a press release announcing rezatapopt monotherapy interim data from its PYNNACLE Phase 2 trial across multiple solid tumors with a TP53 Y220C mutation and hosted an investor webinar to review the Phase 2 interim clinical data. The press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.

The press release attached as Exhibit 99.2 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit Number		Description
99.1		Investor Webinar dated September 10, 2025
99.2		Press Release issued by PMV Pharmaceuticals, Inc., dated September 10, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				PMV Pharmaceuticals, Inc.
Date: September 10, 2025				By:		/s/ Michael Carulli
						Michael Carulli
						Chief Financial Officer (Principal Financial Officer)

FAQ

What did PMV (PMVP) disclose in the 8-K dated September 10, 2025?

The 8-K states PMV issued a press release and held an investor webinar on September 10, 2025 presenting interim monotherapy data for rezatapopt from the PYNNACLE Phase 2 trial in tumors with TP53 Y220C mutation; the press release is attached as Exhibit 99.2.

Does the 8-K include the interim clinical data for rezatapopt?

No. The provided 8-K excerpt notes the release and incorporation of the press release but does not contain the numerical interim data or tables within the filing text.

Where can investors find the detailed interim results mentioned by PMV (PMVP)?

Investors should review the attached Exhibit 99.2 press release and the investor webinar materials referenced in the 8-K for detailed efficacy, safety, and enrollment data.

Was any financial impact or guidance provided in this 8-K for PMV (PMVP)?

No. The excerpt contains no financial results, guidance, or quantified financial impact related to the clinical disclosure.

What trial and mutation are involved in PMV's announcement?

The announcement concerns the PYNNACLE Phase 2 trial of rezatapopt in multiple solid tumors harboring the TP53 Y220C mutation.